期刊文献+

阿贝西利在HR+/HER2-乳腺癌治疗中的应用研究进展

Research progress of abemaciclib in treatment of HR+/HER2-breast cancer
下载PDF
导出
摘要 内分泌治疗是激素受体阳性(Hormone receptor positive type,HR+)、人表皮生长因子受体2阴性(Human epidermal growth factor receptor-2,HER2-)乳腺癌的重要治疗方式,然而多数患者在经过一段时间的治疗后产生耐药性(获得性耐药),且有些患者在初始治疗时便对药物不敏感(原发性耐药)^([1]),因此对该类患者给予内分泌联合靶向治疗是一个新的治疗策略.
作者 孙彩红 全香花 张金铭 元海丹 SUN Caihong;QUAN Xianghua;ZHANG Jinming;YUAN Haidan(Yanbian University College of Pharmacy,Yanji 133002,Jilin,China;Department of Pharmacy,Affiliated Hospital of Qingdao University,Qingdao 266003,Shandong,China)
出处 《延边大学医学学报》 CAS 2023年第3期226-231,共6页 Journal of Medical Science Yanbian University
基金 国家自然科学基金项目(82060674).
  • 相关文献

参考文献8

二级参考文献74

  • 1Lim S, Kaldis P. CDKs cyclins and CKIs: Roles beyond cell cycle regulation [J]. Development, 2013, 140(15): 3079-3093.
  • 2Asghar U, Witkiewicz A K, Turner N C, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy [J]. Nat Rev Drug Diseov, 2015, 14(2): 130-146.
  • 3Cicenas J, Kalyan K, Sorokinas A, et al. Highlights of the latest advances in research on CDK inhibitors [J]. Cancers, 2014, 6(4): 2224- 2242.
  • 4Canavese M, Santo L, Raje N. Cyclin dependent kinases in cancer [J]. Cancer Biol Ther, 2014, 13(7): 451-457.
  • 5Okamoto M, Hidaka A, Toyama M, et al. Selective inhibition of HIV-1 replication by the CDK9 inhibitor FIT-039 [J]. A ntiviral Res, 2015, 123:l-4.
  • 6Guen V J, Gamble C, Flajolet M, et al. CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome [J]. ProcNatlAcadSci USA, 2013, 110(48): 19525-19530.
  • 7Malumbres M. Cyclin-dependent kinases [J]. Genome Biol, 2014, 15(6): 122.
  • 8Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: A changing paradigm [J]. Nat Rev Cancer, 2009, 9(3): 153-166.
  • 9Peyressatre M, Prevel C, Pellerano M, et al. Targeting cyelin-dependent kinases in human cancers: From small molecules to peptide inhibitors [J] Cancers:Basel, 2015, 7(1): 179-237.
  • 10Mariaule G, Belmont P. Cyclin-dependent kinase inhibitors as marketed anticancer drugs: Where are we now? A short survey [J]. Molecules 2014,19(9):14366-14382.

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部